U2Bio Co., Ltd.

Equities

A221800

KR7221800006

Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-17 pm EDT			5-day change	1st Jan Change
3,900 ^KRW	-1.27%		-8.13%	-26.14%

2023	U2Bio Co., Ltd. has filed an IPO.	CI
2020	Chang Moo Jeon acquired 8.5% stake in U2Bio CO. LTD. from MAC Fund, L.P. (Class B), a fund managed by M-Venture Investment, Inc. for KRW 1.6 billion.	CI

NDS Corporation acquired 11.85% stake in U2Bio CO. LTD. for KRW 3.8 billion.

October 04, 2018

NDS Corporation acquired 11.85% stake in U2Bio CO. LTD. (XKON:A221800) for KRW 3.8 billion on October 1, 2018. Under the terms, NDS Corporation acquired 0.23 million shares at KRW 0.02 million per share. NDS Corporation completed the acquisition of 11.85% stake in U2Bio CO. LTD. (XKON:A221800) on October 1, 2018.

Latest news about U2Bio Co., Ltd.

U2Bio Co., Ltd. has filed an IPO.	23-04-12	CI
Chang Moo Jeon acquired 8.5% stake in U2Bio CO. LTD. from MAC Fund, L.P. (Class B), a fund managed by M-Venture Investment, Inc. for KRW 1.6 billion.	20-09-23	CI
U2Bio CO. LTD. announced that it has received KRW 7 billion in funding	19-04-17	CI
U2Bio CO. LTD. announced that it expects to receive KRW 7 billion in funding	19-04-11	CI
NDS Corporation acquired additional 11.9% stake in U2Bio CO. LTD. from BSK Potential Fund 1, fund of BSK Investment for KRW 3.8 billion.	18-10-05	CI
NDS Corporation acquired 11.85% stake in U2Bio CO. LTD. for KRW 3.8 billion.	18-10-04	CI
An undisclosed buyer acquired 5.26% stake in U2Bio CO. LTD. from CKD Venture Fund 4 managed by CKD Venture Capital Co., Ltd. for KRW 1.1 billion.	17-07-11	CI
U2Bio CO. LTD. announced that it has received KRW 1.5 billion in funding	16-08-09	CI
U2Bio CO. LTD. announced that it expects to receive KRW 1.5 billion in funding	16-08-08	CI

Chart U2Bio Co., Ltd.

Duration

Period

More charts

Company Profile

U2BIO CO., LTD. is a Korea-based company mainly engaged in the provision of diagnostic testing services. The Company is involved in the provision of the general diagnostic testing services, molecular diagnostic testing services, as well as medical information technology (IT) services. The general diagnostic testing services include the provision of diagnosis and inspection information such as immunological serology, hematology, urine and microbiology, and pathology excluding molecular diagnostics among in vitro diagnostic tests. The Molecular diagnostic testing services include the provision of diagnostic and testing information through tests such as urethritis, mastoiditis, vaginitis, and cervicitis. The medical IT services include the provision of customized medical services through software products.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
U2BIO CO., LTD.	-26.14%	32.28M
HCA HEALTHCARE, INC.	+25.36%	87.86B
CVS HEALTH CORPORATION	-22.40%	76.69B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.24%	26.86B
FRESENIUS SE & CO. KGAA	+2.00%	17.76B
QUEST DIAGNOSTICS INCORPORATED	-0.44%	15.22B
NATERA, INC.	+75.72%	13.56B
TENET HEALTHCARE CORPORATION	+82.44%	13.37B
PURE HEALTH HOLDING	-24.56%	13.01B
UNIVERSAL HEALTH SERVICES, INC.	+24.79%	12.7B

Other Healthcare Facilities & Services